Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
Rustin
G J
GJ
Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.
Quinnell
T G
TG
Johnson
J
J
Clarke
H
H
Nelstrop
A E
AE
Bollag
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D015474:Isotretinoin; D002117:Calcitriol